OBJECTIVE: To evaluate the economic cost and the incremental costeffectiveness
ratio (ICER) per quality-adjusted life-year (QALY) of pharmaceutical
care in the management of diabetes and hypertension in elderly
patients in a primary public health care system in a developing country.